2008 - Review: Celecoxib increases risk for cardiovascular events; risks are greatest with higher doses

Rothschild, Bruce
September 2008
ACP Journal Club;9/16/2008, Vol. 149 Issue 3, p13
Academic Journal
The article provides an answer to the question if long-term use of celecoxib increase risk for cardiovascular events and if the risk is dose-dependent.


Related Articles

  • Findings Could Reduce COX-2 Inhibitors Risk. Ritsma, Rich // Drug Discovery & Development;May2006, Vol. 9 Issue 5, p8 

    The article reports on the research about why anti-inflammatory drugs such as Celebrex and Vioxx cause cardiovascular problems. The study shows that COX-2 inhibitors introduce cardiovascular risk using the same mechanism by which they reduce pain and inflammation. The likely outcome of aspirin...

  • Celecoxib and cardiovascular risk.  // Reactions Weekly;6/7/2008, Issue 1205, p4 

    The article presents the results of the Celecoxib Cross Trial Safety Analysis, which indicate that different celecoxib doses and regimens are associated with differences in the risk of cardiovascular events. According to six randomised trials which compared celecoxib with placebo, the overall...

  • Celecoxib and rofecoxib have same heart risk.  // GP: General Practitioner;4/22/2005, p7 

    The article cites a study published in the 2005 issue of the journal "Drug Safety" which states that cox-2 inhibitor celecoxib and rofecoxib cause a similar number of adverse cardiovascular events. The study analyzed scrip data from 26,403 patients who took either drug in 2001. They found no...

  • Celecoxib associated with similar cardiovascular risk to rofecoxib.  // Reactions Weekly;4/23/2005, Issue 1048, p5 

    Discusses research being done on the incidence of thrombotic cardiovascular events associated with celecoxib and rofecoxib. Reference to a study by J. Ashton et al, published in a 2005 issue of the "Drug Safety"; Number of patients receiving celecoxib who experienced thrombotic cardiovascular...

  • Celecoxib: increased risk of myocardial infarction.  // Reactions Weekly;3/11/2006, Issue 1092, p4 

    Discusses research being done on the association between celecoxib and the risk of cardiovascular events. Reference to a study by B. Caldwell et al published in the March 2006 issue of the "Journal of the Royal Society of Medicine"; Methodology of the study; Comparison between the risk of...

  • Celecoxib CV risk increased at higher dosages.  // Reactions Weekly;4/12/2008, Issue 1197, p3 

    The article discusses a study of the risk of developing cardiovascular (CV) adverse events in patients receiving high doses of celecoxib, which was presented at the 57th Annual Meeting of the American College of Cardiology. The study involved randomised controlled trials comparing celecoxib with...

  • Pfizer's Celebrex may increase cardiovascular risk.  // PharmaWatch: Monthly Review;Feb2005, Vol. 4 Issue 2, p9 

    The article focuses on the results of a clinical trial announced by Pfizer Inc. pointing on Celebrex to be risky in the cardiovascular system. The cancer trial involved 3,600 patients undergoing medication with Celebrex, in which 2,400 of them have undergone cardiovascular analysis since they...

  • Will the FDA's axe fall on COX-2s?  // PharmaWatch: Monthly Review;Feb2005, Vol. 4 Issue 2, p23 

    The article reports on the effects of the controversies about the cardiovascular dangers of cyclooxygenase-2 inhibitors on the pharmaceutical industry. The withdrawal of Merck & Co.'s Vioxx from the market because of these concerns has brought shockwaves in the sector. Pfizer Inc. has also...

  • journal watch.  // Pulse;2/28/2005, Vol. 65 Issue 8, p11 

    The article reports on various news reports related to medicine, which are published in various journals. "The New England Journal of Medicine" has reported that the cox-2 inhibitor celecoxib may increase the risk of cardiovascular events. Researchers have analyzed cardiovascular events among...

  • COX-2 inhibitor demonstrates lower incidence of adverse cardiorenal events compared with nonselective NSAIDs.  // Formulary;Aug2006, Vol. 41 Issue 8, p372 

    The article reports on the meta-analysis of data set up by parallel-designed, placebo-controlled studies involving 44,000 patients who had been taking cycloxygenase-2(COX-2) inhibitor celecoxib (50-800 mg TTD) can lower incidence of adverse cardiorenal such as hypertension, edema, or congestive...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics